All terms in GO
| Label | Id | Description |
|---|---|---|
| positive regulation by symbiont of host apoptotic process | GO_0052151 |
Any process in which an organism activates, maintains or increases the frequency, rate or extent of programmed cell death in the host, where programmed cell death proceeds by apoptosis. The host is defined as the larger of the organisms involved in a symbiotic interaction.
|
| maternal process involved in parturition | GO_0060137 |
A reproductive process occurring in the mother that results in birth.
|
| regulation of tube length, open tracheal system | GO_0035159 |
Ensuring that a tube in an open tracheal system is of the correct length.
|
| fetal process involved in parturition | GO_0060138 |
A reproductive process occurring in the embryo that results in birth.
|
| positive regulation of antibody-dependent cellular cytotoxicity | GO_0001815 |
Any process that activates or increases the frequency, rate or extent of antibody-dependent cellular cytotoxicity.
|
| regulation of antibody-dependent cellular cytotoxicity | GO_0001813 |
Any process that modulates the frequency, rate, or extent of antibody-dependent cellular cytotoxicity.
|
| FYXD domain binding | GO_0098750 |
Binding to a FXYD domain.
|
| negative regulation of antibody-dependent cellular cytotoxicity | GO_0001814 |
Any process that stops, prevents, or reduces the rate of antibody-dependent cellular cytotoxicity.
|
| terminal cell fate specification, open tracheal system | GO_0035154 |
The process in which a cell in an open tracheal system becomes capable of differentiating autonomously into a terminal cell in an environment that is neutral with respect to the developmental pathway; upon specification, the cell fate can be reversed. Terminal cells send long and bifurcated hollow branches toward target tissues to allow oxygen exchange.
|
| negative regulation of type I hypersensitivity | GO_0001811 |
Any process that stops, prevents, or reduces the rate of type I hypersensitivity, a type of inflammatory response.
|
| regulation of type I hypersensitivity | GO_0001810 |
Any process that modulates the frequency, rate, or extent of type I hypersensitivity, a type of inflammatory response.
|
| negative regulation of hypersensitivity | GO_0002884 |
Any process that stops, prevents, or reduces the frequency, rate, or extent of hypersensitivity.
|
| integral component of the cytoplasmic side of the plasma membrane | GO_0098752 |
The component of the plasma membrane consisting of the gene products that penetrate only the cytoplasmic side of the membrane.
|
| positive regulation of type I hypersensitivity | GO_0001812 |
Any process that activates or increases the frequency, rate or extent of type I hypersensitivity, a type of inflammatory response.
|
| positive regulation of hypersensitivity | GO_0002885 |
Any process that activates or increases the frequency, rate, or extent of hypersensitivity.
|
| anchored component of the cytoplasmic side of the plasma membrane | GO_0098753 |
The component of the plasma membrane consisting of gene products and protein complexes with covalently attached hydrophobic anchors products that penetrate only the cytoplasmic side of the membrane.
|
| regulation of hypersensitivity | GO_0002883 |
Any process that modulates the frequency, rate, or extent of hypersensitivity.
|
| maintenance of seed dormancy by absisic acid | GO_0098755 |
The process by which seed dormancy is maintained by the presence of absisic acid.
|
| response to interleukin-21 | GO_0098756 |
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-21 stimulus.
|
| cellular response to interleukin-21 | GO_0098757 |
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-21 stimulus.
|